| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Endophthalmitis | 19 | 2017 | 257 | 2.980 |
Why?
|
| Eye Infections, Bacterial | 17 | 2023 | 239 | 2.050 |
Why?
|
| Free Tissue Flaps | 5 | 2018 | 327 | 1.650 |
Why?
|
| Surgical Wound Infection | 9 | 2021 | 1526 | 1.600 |
Why?
|
| Mycoses | 7 | 2017 | 386 | 1.470 |
Why?
|
| Keratitis | 5 | 2021 | 239 | 1.130 |
Why?
|
| Eye Infections | 3 | 2023 | 62 | 1.050 |
Why?
|
| Surgical Flaps | 4 | 2021 | 1669 | 1.020 |
Why?
|
| Eye Infections, Fungal | 8 | 2021 | 100 | 1.010 |
Why?
|
| Antibiotic Prophylaxis | 6 | 2016 | 642 | 0.990 |
Why?
|
| Prosthesis-Related Infections | 6 | 2016 | 486 | 0.960 |
Why?
|
| Bacterial Infections | 5 | 2017 | 1401 | 0.900 |
Why?
|
| Herpes Zoster Ophthalmicus | 3 | 2021 | 37 | 0.860 |
Why?
|
| Aspergillosis | 3 | 2021 | 243 | 0.860 |
Why?
|
| Head and Neck Neoplasms | 8 | 2021 | 2882 | 0.850 |
Why?
|
| Mucormycosis | 2 | 2021 | 103 | 0.830 |
Why?
|
| Anti-Bacterial Agents | 24 | 2020 | 7403 | 0.680 |
Why?
|
| Retinal Necrosis Syndrome, Acute | 2 | 2016 | 24 | 0.680 |
Why?
|
| Sinusitis | 5 | 2021 | 990 | 0.650 |
Why?
|
| Eye Infections, Viral | 2 | 2016 | 60 | 0.610 |
Why?
|
| Vitrectomy | 9 | 2017 | 391 | 0.600 |
Why?
|
| Urinary Tract Infections | 2 | 2021 | 812 | 0.570 |
Why?
|
| Foscarnet | 1 | 2016 | 35 | 0.560 |
Why?
|
| Antifungal Agents | 7 | 2021 | 749 | 0.560 |
Why?
|
| Eye Infections, Parasitic | 3 | 2018 | 25 | 0.550 |
Why?
|
| Polymyxins | 1 | 2016 | 19 | 0.550 |
Why?
|
| Trimethoprim | 1 | 2016 | 83 | 0.530 |
Why?
|
| Cytosine | 1 | 2016 | 210 | 0.500 |
Why?
|
| Histoplasma | 1 | 2014 | 39 | 0.480 |
Why?
|
| Cornea | 5 | 2010 | 1326 | 0.480 |
Why?
|
| Bacteria | 6 | 2017 | 2197 | 0.480 |
Why?
|
| Clostridium Infections | 1 | 2021 | 557 | 0.480 |
Why?
|
| Bacteremia | 1 | 2021 | 980 | 0.470 |
Why?
|
| Histoplasmosis | 1 | 2014 | 63 | 0.470 |
Why?
|
| Palatine Tonsil | 1 | 2014 | 193 | 0.460 |
Why?
|
| Vitreous Body | 6 | 2016 | 399 | 0.450 |
Why?
|
| Ophthalmologic Surgical Procedures | 3 | 2015 | 353 | 0.450 |
Why?
|
| Eye | 2 | 2023 | 710 | 0.440 |
Why?
|
| Syphilis | 4 | 2023 | 243 | 0.440 |
Why?
|
| Pharyngeal Diseases | 1 | 2014 | 134 | 0.440 |
Why?
|
| Otorhinolaryngologic Surgical Procedures | 1 | 2016 | 323 | 0.430 |
Why?
|
| Herpes Simplex | 1 | 2016 | 478 | 0.420 |
Why?
|
| Microsurgery | 1 | 2018 | 796 | 0.410 |
Why?
|
| Orbital Cellulitis | 2 | 2009 | 33 | 0.380 |
Why?
|
| Triazoles | 3 | 2021 | 902 | 0.380 |
Why?
|
| Laryngeal Diseases | 1 | 2014 | 243 | 0.380 |
Why?
|
| Toxocara | 1 | 2011 | 1 | 0.380 |
Why?
|
| Toxocariasis | 1 | 2011 | 12 | 0.380 |
Why?
|
| Antiparasitic Agents | 1 | 2011 | 43 | 0.370 |
Why?
|
| Clindamycin | 2 | 2016 | 140 | 0.360 |
Why?
|
| Eyelid Diseases | 3 | 2018 | 157 | 0.350 |
Why?
|
| Ethmoid Sinus | 1 | 2010 | 57 | 0.350 |
Why?
|
| Aqueous Humor | 2 | 2010 | 153 | 0.340 |
Why?
|
| Pneumonia | 1 | 2021 | 2129 | 0.340 |
Why?
|
| Vancomycin | 2 | 2011 | 503 | 0.340 |
Why?
|
| Corneal Ulcer | 4 | 2016 | 128 | 0.330 |
Why?
|
| Fusarium | 2 | 2007 | 51 | 0.320 |
Why?
|
| Glaucoma Drainage Implants | 1 | 2010 | 106 | 0.310 |
Why?
|
| Artificial Organs | 1 | 2010 | 149 | 0.310 |
Why?
|
| Maxillary Sinus | 1 | 2010 | 180 | 0.310 |
Why?
|
| Abscess | 2 | 2010 | 605 | 0.310 |
Why?
|
| Prosthesis Implantation | 3 | 2009 | 590 | 0.300 |
Why?
|
| Lacrimal Apparatus | 1 | 2010 | 223 | 0.300 |
Why?
|
| Dacryocystitis | 1 | 2008 | 68 | 0.300 |
Why?
|
| Orbital Diseases | 4 | 2015 | 178 | 0.300 |
Why?
|
| Gram-Negative Bacterial Infections | 2 | 2008 | 237 | 0.290 |
Why?
|
| Eye Injuries, Penetrating | 1 | 2009 | 121 | 0.280 |
Why?
|
| Antiviral Agents | 3 | 2016 | 3056 | 0.280 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 3 | 2021 | 694 | 0.260 |
Why?
|
| Contact Lenses | 2 | 2021 | 138 | 0.260 |
Why?
|
| Fungi | 3 | 2017 | 339 | 0.250 |
Why?
|
| Heart-Assist Devices | 1 | 2016 | 1279 | 0.250 |
Why?
|
| Herpesvirus 3, Human | 2 | 2016 | 158 | 0.250 |
Why?
|
| Aspergillus fumigatus | 1 | 2005 | 156 | 0.230 |
Why?
|
| Drug Therapy, Combination | 7 | 2007 | 6293 | 0.230 |
Why?
|
| Streptococcal Infections | 1 | 2008 | 617 | 0.220 |
Why?
|
| Fasciitis, Necrotizing | 1 | 2004 | 79 | 0.220 |
Why?
|
| Treponema pallidum | 1 | 2023 | 47 | 0.220 |
Why?
|
| Staphylococcal Infections | 4 | 2016 | 1406 | 0.220 |
Why?
|
| Facial Paralysis | 2 | 2021 | 345 | 0.220 |
Why?
|
| Peptides, Cyclic | 1 | 2005 | 392 | 0.220 |
Why?
|
| Drug Resistance, Bacterial | 2 | 2015 | 1055 | 0.220 |
Why?
|
| Patient Readmission | 1 | 2017 | 3261 | 0.210 |
Why?
|
| Postoperative Complications | 8 | 2017 | 15637 | 0.210 |
Why?
|
| Gram-Positive Bacterial Infections | 3 | 2015 | 343 | 0.210 |
Why?
|
| Retrospective Studies | 20 | 2021 | 80168 | 0.210 |
Why?
|
| Acanthamoeba Keratitis | 1 | 2021 | 12 | 0.200 |
Why?
|
| Streptococcus pyogenes | 1 | 2004 | 294 | 0.200 |
Why?
|
| Eye Evisceration | 2 | 2013 | 22 | 0.190 |
Why?
|
| Humans | 75 | 2023 | 758406 | 0.190 |
Why?
|
| Bell Palsy | 1 | 2021 | 39 | 0.190 |
Why?
|
| Achromobacter | 1 | 2021 | 8 | 0.190 |
Why?
|
| Keratitis, Herpetic | 1 | 2021 | 77 | 0.190 |
Why?
|
| Cataract Extraction | 4 | 2012 | 465 | 0.180 |
Why?
|
| Aged | 27 | 2023 | 168218 | 0.180 |
Why?
|
| Organ Preservation Solutions | 1 | 2021 | 100 | 0.180 |
Why?
|
| Ophthalmic Solutions | 1 | 2021 | 304 | 0.170 |
Why?
|
| Drug Contamination | 1 | 2021 | 152 | 0.170 |
Why?
|
| Limbus Corneae | 1 | 2021 | 144 | 0.160 |
Why?
|
| Massachusetts | 3 | 2017 | 8823 | 0.160 |
Why?
|
| Middle Aged | 35 | 2023 | 219568 | 0.160 |
Why?
|
| Risk Factors | 14 | 2021 | 73809 | 0.160 |
Why?
|
| Incidence | 8 | 2016 | 21272 | 0.160 |
Why?
|
| DNA, Bacterial | 1 | 2023 | 1456 | 0.160 |
Why?
|
| Simuliidae | 1 | 1998 | 5 | 0.150 |
Why?
|
| Onchocerciasis, Ocular | 1 | 1998 | 7 | 0.150 |
Why?
|
| Infusions, Intravenous | 2 | 2016 | 2210 | 0.150 |
Why?
|
| Catheter-Related Infections | 1 | 2021 | 273 | 0.150 |
Why?
|
| Myiasis | 1 | 2018 | 14 | 0.150 |
Why?
|
| Administration, Topical | 2 | 2016 | 697 | 0.150 |
Why?
|
| Onchocerca volvulus | 1 | 1998 | 15 | 0.150 |
Why?
|
| Diptera | 1 | 2018 | 50 | 0.150 |
Why?
|
| Glossectomy | 1 | 2018 | 60 | 0.150 |
Why?
|
| Anti-Infective Agents | 3 | 2013 | 981 | 0.150 |
Why?
|
| Combined Modality Therapy | 6 | 2016 | 8530 | 0.150 |
Why?
|
| Follow-Up Studies | 12 | 2018 | 39059 | 0.140 |
Why?
|
| Polymerase Chain Reaction | 4 | 2023 | 6068 | 0.140 |
Why?
|
| Visual Acuity | 3 | 2009 | 2642 | 0.140 |
Why?
|
| Nitriles | 1 | 2021 | 957 | 0.130 |
Why?
|
| Cutaneous Fistula | 1 | 2016 | 79 | 0.130 |
Why?
|
| Actinomycetaceae | 1 | 2015 | 5 | 0.130 |
Why?
|
| Eye Enucleation | 2 | 2013 | 128 | 0.130 |
Why?
|
| Microbial Sensitivity Tests | 5 | 2021 | 1945 | 0.130 |
Why?
|
| Tongue Neoplasms | 1 | 2018 | 183 | 0.130 |
Why?
|
| Toxoplasmosis, Ocular | 1 | 2015 | 29 | 0.130 |
Why?
|
| Eyelids | 1 | 2018 | 277 | 0.130 |
Why?
|
| Eye Diseases | 3 | 2009 | 651 | 0.120 |
Why?
|
| Risk Assessment | 3 | 2014 | 23884 | 0.120 |
Why?
|
| Lacrimal Apparatus Diseases | 1 | 1996 | 72 | 0.120 |
Why?
|
| Paecilomyces | 1 | 2014 | 3 | 0.120 |
Why?
|
| Keratoplasty, Penetrating | 4 | 2021 | 144 | 0.120 |
Why?
|
| Conjunctivitis | 1 | 1996 | 155 | 0.120 |
Why?
|
| beta-Lactamases | 1 | 2016 | 304 | 0.120 |
Why?
|
| Toxoplasma | 1 | 2015 | 151 | 0.120 |
Why?
|
| Otolaryngology | 1 | 2021 | 685 | 0.120 |
Why?
|
| Antibodies, Protozoan | 1 | 2015 | 251 | 0.120 |
Why?
|
| Intravitreal Injections | 2 | 2015 | 384 | 0.120 |
Why?
|
| Corneal Diseases | 3 | 2010 | 536 | 0.110 |
Why?
|
| Oropharynx | 1 | 2014 | 133 | 0.110 |
Why?
|
| Optic Neuritis | 1 | 2016 | 174 | 0.110 |
Why?
|
| Male | 37 | 2023 | 358747 | 0.110 |
Why?
|
| Lymphopenia | 1 | 2015 | 280 | 0.110 |
Why?
|
| Pyrimidines | 1 | 2005 | 3006 | 0.110 |
Why?
|
| Staphylococcus aureus | 2 | 2015 | 1460 | 0.110 |
Why?
|
| Rhinitis | 1 | 2020 | 746 | 0.110 |
Why?
|
| Pharyngitis | 1 | 2014 | 219 | 0.110 |
Why?
|
| Simplexvirus | 1 | 2016 | 803 | 0.100 |
Why?
|
| Device Removal | 1 | 2018 | 633 | 0.100 |
Why?
|
| Female | 30 | 2023 | 390323 | 0.100 |
Why?
|
| Biopsy, Needle | 1 | 2018 | 1630 | 0.100 |
Why?
|
| Escherichia coli Infections | 1 | 2016 | 523 | 0.100 |
Why?
|
| Diagnosis, Differential | 8 | 2016 | 12951 | 0.100 |
Why?
|
| Length of Stay | 2 | 2016 | 6439 | 0.100 |
Why?
|
| Debridement | 3 | 2015 | 492 | 0.100 |
Why?
|
| Wound Healing | 3 | 2018 | 2783 | 0.100 |
Why?
|
| Stevens-Johnson Syndrome | 2 | 2009 | 244 | 0.100 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2016 | 586 | 0.100 |
Why?
|
| Eye Burns | 2 | 2009 | 65 | 0.100 |
Why?
|
| Pythium | 1 | 2011 | 1 | 0.100 |
Why?
|
| Pythiosis | 1 | 2011 | 1 | 0.100 |
Why?
|
| Young Adult | 11 | 2017 | 58808 | 0.100 |
Why?
|
| Exanthema | 1 | 2016 | 504 | 0.100 |
Why?
|
| Bioprosthesis | 1 | 2016 | 591 | 0.090 |
Why?
|
| Sulfadiazine | 1 | 2010 | 18 | 0.090 |
Why?
|
| Aspergillus niger | 1 | 2010 | 18 | 0.090 |
Why?
|
| Meningitis, Bacterial | 1 | 1993 | 221 | 0.090 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2018 | 4023 | 0.090 |
Why?
|
| Reoperation | 3 | 2018 | 4282 | 0.090 |
Why?
|
| Virulence | 3 | 2016 | 1298 | 0.090 |
Why?
|
| Adult | 24 | 2023 | 219935 | 0.090 |
Why?
|
| Vancomycin Resistance | 1 | 2011 | 126 | 0.090 |
Why?
|
| Bacterial Typing Techniques | 2 | 2023 | 260 | 0.090 |
Why?
|
| Retropharyngeal Abscess | 1 | 2010 | 21 | 0.090 |
Why?
|
| Gram-Positive Cocci | 1 | 2009 | 8 | 0.090 |
Why?
|
| Eye Injuries | 1 | 2013 | 227 | 0.090 |
Why?
|
| Virus Diseases | 1 | 1996 | 719 | 0.080 |
Why?
|
| Pyridines | 1 | 2021 | 2859 | 0.080 |
Why?
|
| Haemophilus paraphrophilus | 1 | 2008 | 1 | 0.080 |
Why?
|
| Aneurysm, Infected | 1 | 2009 | 81 | 0.080 |
Why?
|
| Eikenella corrodens | 1 | 2008 | 17 | 0.080 |
Why?
|
| Pemphigoid, Benign Mucous Membrane | 1 | 2009 | 115 | 0.080 |
Why?
|
| Streptococcus anginosus | 1 | 2008 | 24 | 0.080 |
Why?
|
| Crowns | 1 | 2009 | 155 | 0.080 |
Why?
|
| Addison Disease | 1 | 2009 | 48 | 0.080 |
Why?
|
| Chemoprevention | 1 | 2011 | 326 | 0.080 |
Why?
|
| Chronic Disease | 5 | 2020 | 9267 | 0.080 |
Why?
|
| Treatment Outcome | 9 | 2020 | 64378 | 0.070 |
Why?
|
| Streptococcus agalactiae | 1 | 2009 | 337 | 0.070 |
Why?
|
| Aged, 80 and over | 8 | 2016 | 58683 | 0.070 |
Why?
|
| Immunocompromised Host | 1 | 2013 | 856 | 0.070 |
Why?
|
| Hearing Loss, Sudden | 1 | 2008 | 45 | 0.070 |
Why?
|
| Temporal Arteries | 1 | 2008 | 148 | 0.070 |
Why?
|
| Venous Thrombosis | 1 | 2016 | 1292 | 0.070 |
Why?
|
| Alternaria | 1 | 2007 | 42 | 0.070 |
Why?
|
| Carotid Artery, Internal | 1 | 2009 | 435 | 0.070 |
Why?
|
| Dura Mater | 1 | 2008 | 290 | 0.070 |
Why?
|
| Prostheses and Implants | 2 | 2005 | 1270 | 0.070 |
Why?
|
| Focal Infection, Dental | 1 | 2006 | 25 | 0.070 |
Why?
|
| Drainage | 2 | 2010 | 1161 | 0.070 |
Why?
|
| Candida | 1 | 2007 | 173 | 0.060 |
Why?
|
| Orbit Evisceration | 1 | 2005 | 9 | 0.060 |
Why?
|
| Echinocandins | 1 | 2005 | 51 | 0.060 |
Why?
|
| Corneal Transplantation | 1 | 2009 | 321 | 0.060 |
Why?
|
| Leishmaniasis, Mucocutaneous | 1 | 2005 | 14 | 0.060 |
Why?
|
| Leishmania braziliensis | 1 | 2005 | 16 | 0.060 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2016 | 6493 | 0.060 |
Why?
|
| Lipopeptides | 1 | 2005 | 72 | 0.060 |
Why?
|
| Granuloma, Pyogenic | 1 | 2005 | 47 | 0.060 |
Why?
|
| Quality Assurance, Health Care | 1 | 2015 | 2167 | 0.060 |
Why?
|
| Guideline Adherence | 1 | 2015 | 2215 | 0.060 |
Why?
|
| Meningitis, Meningococcal | 1 | 2004 | 44 | 0.060 |
Why?
|
| Keratoconjunctivitis | 1 | 2004 | 40 | 0.060 |
Why?
|
| Glucocorticoids | 3 | 2009 | 2144 | 0.060 |
Why?
|
| Giant Cell Arteritis | 1 | 2008 | 297 | 0.060 |
Why?
|
| Neisseria meningitidis | 1 | 2004 | 107 | 0.060 |
Why?
|
| Biopsy | 2 | 2014 | 6768 | 0.060 |
Why?
|
| Escherichia coli | 1 | 2016 | 4215 | 0.060 |
Why?
|
| Cellulitis | 1 | 2006 | 207 | 0.060 |
Why?
|
| Immunohistochemistry | 1 | 2018 | 11070 | 0.060 |
Why?
|
| Intraocular Pressure | 1 | 2010 | 1288 | 0.060 |
Why?
|
| Lens Implantation, Intraocular | 1 | 2005 | 190 | 0.060 |
Why?
|
| Cicatrix | 1 | 2009 | 781 | 0.060 |
Why?
|
| Immunoglobulin G | 1 | 2015 | 4540 | 0.060 |
Why?
|
| Cross Infection | 1 | 1993 | 1432 | 0.060 |
Why?
|
| Molecular Typing | 1 | 2023 | 116 | 0.050 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2015 | 4353 | 0.050 |
Why?
|
| Bone Marrow Transplantation | 1 | 2011 | 2693 | 0.050 |
Why?
|
| Time Factors | 3 | 2016 | 39872 | 0.050 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 2023 | 763 | 0.050 |
Why?
|
| Uveitis | 2 | 2016 | 393 | 0.050 |
Why?
|
| Immunoconjugates | 1 | 2010 | 949 | 0.050 |
Why?
|
| Carotid Stenosis | 1 | 2009 | 853 | 0.050 |
Why?
|
| Hearing Loss, Sensorineural | 1 | 2008 | 781 | 0.050 |
Why?
|
| Dexamethasone | 1 | 2009 | 1927 | 0.050 |
Why?
|
| Encephalomyelitis, Eastern Equine | 1 | 2001 | 14 | 0.050 |
Why?
|
| Attitude of Health Personnel | 1 | 2015 | 3867 | 0.050 |
Why?
|
| Equipment Design | 1 | 2009 | 3507 | 0.050 |
Why?
|
| Adolescent | 8 | 2015 | 87892 | 0.050 |
Why?
|
| Eye Banks | 1 | 2021 | 40 | 0.050 |
Why?
|
| Immunosuppressive Agents | 2 | 2012 | 4158 | 0.040 |
Why?
|
| Candida albicans | 2 | 2001 | 374 | 0.040 |
Why?
|
| Diabetic Foot | 1 | 2004 | 380 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 6 | 2010 | 20500 | 0.040 |
Why?
|
| Glaucoma | 1 | 2010 | 1182 | 0.040 |
Why?
|
| DNA, Ribosomal | 1 | 2021 | 285 | 0.040 |
Why?
|
| Bacteriological Techniques | 1 | 2021 | 279 | 0.040 |
Why?
|
| Immunity, Cellular | 1 | 2005 | 1557 | 0.040 |
Why?
|
| Cohort Studies | 3 | 2017 | 41256 | 0.040 |
Why?
|
| Prevalence | 2 | 2011 | 15651 | 0.040 |
Why?
|
| Vision, Monocular | 1 | 1999 | 71 | 0.040 |
Why?
|
| Mycobacterium Infections | 1 | 1999 | 121 | 0.040 |
Why?
|
| Candidiasis | 1 | 2001 | 363 | 0.040 |
Why?
|
| Graft vs Host Disease | 1 | 2011 | 3024 | 0.040 |
Why?
|
| Tissue and Organ Harvesting | 1 | 2021 | 373 | 0.040 |
Why?
|
| Sequence Analysis, DNA | 2 | 2023 | 4711 | 0.040 |
Why?
|
| Drug Administration Routes | 1 | 1997 | 150 | 0.040 |
Why?
|
| CD4 Lymphocyte Count | 2 | 2015 | 2569 | 0.040 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2021 | 1006 | 0.030 |
Why?
|
| Anterior Eye Segment | 1 | 1998 | 141 | 0.030 |
Why?
|
| Syphilis Serodiagnosis | 1 | 2016 | 37 | 0.030 |
Why?
|
| Latin America | 1 | 1998 | 405 | 0.030 |
Why?
|
| Vision Disorders | 2 | 2016 | 1084 | 0.030 |
Why?
|
| HIV Infections | 3 | 2016 | 17275 | 0.030 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2001 | 664 | 0.030 |
Why?
|
| Graft Rejection | 1 | 2009 | 4426 | 0.030 |
Why?
|
| Neurosyphilis | 1 | 2016 | 27 | 0.030 |
Why?
|
| Administration, Oral | 2 | 2014 | 3991 | 0.030 |
Why?
|
| Host-Parasite Interactions | 1 | 1998 | 301 | 0.030 |
Why?
|
| Chorioretinitis | 1 | 2015 | 43 | 0.030 |
Why?
|
| Anterior Chamber | 2 | 2011 | 194 | 0.030 |
Why?
|
| Africa | 1 | 1998 | 706 | 0.030 |
Why?
|
| Lyme Neuroborreliosis | 1 | 2016 | 50 | 0.030 |
Why?
|
| Mucorales | 1 | 2015 | 35 | 0.030 |
Why?
|
| Aspergillus | 1 | 2015 | 92 | 0.030 |
Why?
|
| Child | 6 | 2021 | 79818 | 0.030 |
Why?
|
| Acyclovir | 1 | 2015 | 268 | 0.030 |
Why?
|
| Lenses, Intraocular | 1 | 1996 | 138 | 0.030 |
Why?
|
| Argentina | 1 | 2015 | 245 | 0.030 |
Why?
|
| HIV Seronegativity | 1 | 2015 | 211 | 0.030 |
Why?
|
| New Zealand | 1 | 2015 | 352 | 0.030 |
Why?
|
| Tissue Donors | 2 | 2021 | 2311 | 0.030 |
Why?
|
| Republic of Korea | 1 | 2016 | 565 | 0.030 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2010 | 3755 | 0.030 |
Why?
|
| Hyperbaric Oxygenation | 1 | 2015 | 165 | 0.030 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 1998 | 662 | 0.030 |
Why?
|
| Gait Disorders, Neurologic | 1 | 2016 | 238 | 0.030 |
Why?
|
| Valine | 1 | 2015 | 408 | 0.030 |
Why?
|
| Arthritis, Psoriatic | 1 | 2016 | 219 | 0.030 |
Why?
|
| Drug Resistance, Microbial | 1 | 1996 | 856 | 0.030 |
Why?
|
| Italy | 1 | 2015 | 839 | 0.030 |
Why?
|
| HIV-1 | 1 | 2010 | 6850 | 0.030 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2011 | 5649 | 0.030 |
Why?
|
| Neuromyelitis Optica | 1 | 2016 | 259 | 0.020 |
Why?
|
| Predictive Value of Tests | 2 | 2015 | 15225 | 0.020 |
Why?
|
| Suppuration | 1 | 2011 | 61 | 0.020 |
Why?
|
| Fever | 2 | 2009 | 1617 | 0.020 |
Why?
|
| Child, Preschool | 3 | 2010 | 42062 | 0.020 |
Why?
|
| Phagocytosis | 1 | 2016 | 1533 | 0.020 |
Why?
|
| Endoscopy | 1 | 2020 | 1834 | 0.020 |
Why?
|
| Early Diagnosis | 1 | 2015 | 1177 | 0.020 |
Why?
|
| Uveitis, Posterior | 1 | 2010 | 45 | 0.020 |
Why?
|
| Cardiolipins | 1 | 2010 | 81 | 0.020 |
Why?
|
| United States | 3 | 2016 | 72136 | 0.020 |
Why?
|
| Severity of Illness Index | 2 | 2008 | 15785 | 0.020 |
Why?
|
| Fluorescein Angiography | 1 | 2015 | 1044 | 0.020 |
Why?
|
| Sarcoidosis | 1 | 2016 | 520 | 0.020 |
Why?
|
| Canada | 1 | 2015 | 2111 | 0.020 |
Why?
|
| Internationality | 1 | 2015 | 1000 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2015 | 2925 | 0.020 |
Why?
|
| Recurrence | 2 | 2011 | 8426 | 0.020 |
Why?
|
| Fundus Oculi | 1 | 2010 | 540 | 0.020 |
Why?
|
| Dehydration | 1 | 2010 | 216 | 0.020 |
Why?
|
| Polyuria | 1 | 2008 | 37 | 0.020 |
Why?
|
| Genotype | 1 | 2023 | 12945 | 0.020 |
Why?
|
| Hearing Loss | 1 | 2016 | 780 | 0.020 |
Why?
|
| Phosphatidylcholines | 1 | 2010 | 405 | 0.020 |
Why?
|
| Ophthalmology | 1 | 2015 | 549 | 0.020 |
Why?
|
| Israel | 1 | 2011 | 721 | 0.020 |
Why?
|
| India | 1 | 2015 | 2329 | 0.020 |
Why?
|
| Animals | 4 | 2018 | 167768 | 0.020 |
Why?
|
| Urinalysis | 1 | 2010 | 368 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2015 | 3801 | 0.020 |
Why?
|
| Pneumococcal Infections | 1 | 1993 | 503 | 0.020 |
Why?
|
| Health Care Surveys | 1 | 2015 | 2432 | 0.020 |
Why?
|
| Cerebrospinal Fluid | 1 | 2010 | 544 | 0.020 |
Why?
|
| Audiometry, Pure-Tone | 1 | 2008 | 210 | 0.020 |
Why?
|
| Steroids | 1 | 2012 | 926 | 0.020 |
Why?
|
| Sensitivity and Specificity | 2 | 2015 | 14641 | 0.020 |
Why?
|
| Spinal Puncture | 1 | 2008 | 281 | 0.020 |
Why?
|
| Postoperative Care | 1 | 2013 | 1471 | 0.020 |
Why?
|
| Infant | 1 | 2009 | 36055 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2000 | 5952 | 0.020 |
Why?
|
| Saphenous Vein | 1 | 2009 | 517 | 0.020 |
Why?
|
| Leukocyte Count | 1 | 2010 | 1593 | 0.020 |
Why?
|
| Auditory Threshold | 1 | 2008 | 369 | 0.020 |
Why?
|
| Cochlear Nerve | 1 | 2008 | 202 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2015 | 6354 | 0.020 |
Why?
|
| Nafcillin | 1 | 2005 | 23 | 0.020 |
Why?
|
| Antimony Sodium Gluconate | 1 | 2005 | 10 | 0.020 |
Why?
|
| Boston | 2 | 2001 | 9304 | 0.020 |
Why?
|
| Trypanocidal Agents | 1 | 2005 | 41 | 0.020 |
Why?
|
| Polymethyl Methacrylate | 1 | 2005 | 131 | 0.020 |
Why?
|
| Burns, Chemical | 1 | 2005 | 122 | 0.020 |
Why?
|
| Nose Diseases | 1 | 2005 | 79 | 0.010 |
Why?
|
| Conjunctival Neoplasms | 1 | 2005 | 77 | 0.010 |
Why?
|
| Muscular Diseases | 1 | 2008 | 551 | 0.010 |
Why?
|
| Prednisone | 1 | 2008 | 1565 | 0.010 |
Why?
|
| Bone Cements | 1 | 2005 | 324 | 0.010 |
Why?
|
| Ceftriaxone | 1 | 2004 | 175 | 0.010 |
Why?
|
| Hospital Mortality | 2 | 1997 | 5272 | 0.010 |
Why?
|
| Odds Ratio | 1 | 2015 | 9650 | 0.010 |
Why?
|
| Nasal Obstruction | 1 | 2005 | 159 | 0.010 |
Why?
|
| Injections | 1 | 2005 | 830 | 0.010 |
Why?
|
| Tomography, Optical Coherence | 1 | 2015 | 2877 | 0.010 |
Why?
|
| Acute Disease | 1 | 1993 | 7225 | 0.010 |
Why?
|
| RNA, Viral | 1 | 2010 | 2836 | 0.010 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2010 | 1895 | 0.010 |
Why?
|
| Pain | 2 | 2009 | 5065 | 0.010 |
Why?
|
| Penicillins | 1 | 2004 | 406 | 0.010 |
Why?
|
| Cholesterol | 1 | 2010 | 2902 | 0.010 |
Why?
|
| Nose | 1 | 2005 | 519 | 0.010 |
Why?
|
| Prospective Studies | 2 | 2015 | 54137 | 0.010 |
Why?
|
| Amphotericin B | 1 | 2001 | 142 | 0.010 |
Why?
|
| Headache | 1 | 2008 | 1248 | 0.010 |
Why?
|
| Vascular Surgical Procedures | 1 | 2009 | 1470 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 1996 | 7985 | 0.010 |
Why?
|
| Gram-Positive Bacteria | 1 | 2001 | 178 | 0.010 |
Why?
|
| Seizures | 1 | 1993 | 2919 | 0.010 |
Why?
|
| Amikacin | 1 | 1999 | 48 | 0.010 |
Why?
|
| Quality of Life | 1 | 2020 | 13285 | 0.010 |
Why?
|
| Asthma | 1 | 1997 | 6172 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2012 | 8553 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2008 | 36284 | 0.010 |
Why?
|
| Acute Kidney Injury | 1 | 2010 | 1926 | 0.010 |
Why?
|
| Status Asthmaticus | 1 | 1997 | 22 | 0.010 |
Why?
|
| Sympathomimetics | 1 | 1997 | 56 | 0.010 |
Why?
|
| Radiography | 1 | 2008 | 6954 | 0.010 |
Why?
|
| Azithromycin | 1 | 1999 | 200 | 0.010 |
Why?
|
| Mycobacterium | 1 | 1999 | 250 | 0.010 |
Why?
|
| Neoplasm Invasiveness | 1 | 2005 | 3617 | 0.010 |
Why?
|
| France | 1 | 1997 | 499 | 0.010 |
Why?
|
| Adrenergic beta-Agonists | 1 | 1997 | 344 | 0.010 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2008 | 1852 | 0.010 |
Why?
|
| Prognosis | 1 | 2016 | 29557 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2015 | 25956 | 0.010 |
Why?
|
| Disease Progression | 1 | 2011 | 13468 | 0.010 |
Why?
|
| Epithelial Cells | 1 | 2005 | 3664 | 0.010 |
Why?
|
| Anti-Asthmatic Agents | 1 | 1997 | 565 | 0.010 |
Why?
|
| Dyspnea | 1 | 1997 | 1344 | 0.010 |
Why?
|
| Forecasting | 1 | 1997 | 2923 | 0.000 |
Why?
|
| Brain | 2 | 2008 | 26947 | 0.000 |
Why?
|
| Cause of Death | 1 | 1997 | 3675 | 0.000 |
Why?
|
| Melanoma | 1 | 2005 | 5691 | 0.000 |
Why?
|
| Critical Care | 1 | 1997 | 2692 | 0.000 |
Why?
|
| Survival Rate | 1 | 1997 | 12721 | 0.000 |
Why?
|
| Proportional Hazards Models | 1 | 1997 | 12440 | 0.000 |
Why?
|
| Age Factors | 1 | 1997 | 18358 | 0.000 |
Why?
|
| Hospitalization | 1 | 1997 | 10652 | 0.000 |
Why?
|